231 results
Page 3 of 12
6-K
EX-99.1
iyg0sn6a8p6q3v76lc
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-2.1
92wlj8425vcx9e474 cg
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-2.1
poq45orjdjvxxjlcqu4h
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-99.1
o5sr7
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.1
g7afjwvnn mbcnl7jl
31 Mar 22
Portage Biotech Provides Update on Clinical-Stage and Development Programs
8:00am
20-F/A
emy vcl50ls1z
3 Mar 22
Annual report (foreign) (amended)
6:57pm
6-K
EX-99.2
k4hptlqnw
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
u8443
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
r9wiiy 4khuub
25 Feb 22
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
12:00am
6-K
EX-99.1
0n2l9xwft0
15 Feb 22
Portage Biotech Announces New Appointments to its Management Team and Board of Directors
8:00am
6-K
EX-99.1
0ggrqodf1qgfr2
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.2
h6xq3q bc56een7ie50t
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.1
0n2ub9nvtwbrc
23 Nov 21
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
8:00am
6-K
hzzec4t5ucot
30 Aug 21
Current report (foreign)
5:21pm
6-K
EX-99.2
yn42bwgem8vybp
30 Aug 21
Current report (foreign)
5:21pm
6-K
EX-99.1
vhqds1xbl6a4
30 Aug 21
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
8:00am
6-K
EX-99.1
wcb 2erso7k79
12 Aug 21
Portage Biotech Issues Letter to Shareholders
10:01am
6-K
EX-99.1
gtu4knkthxe1529rgx3
28 Jul 21
Current report (foreign)
9:37am
SUPPL
ktax df8d
24 Jun 21
Supplemental materials (foreign)
5:27pm